The spouse of a patient newly diagnosed with mild, unilateral symptoms of Parkinson disease (PD) asks the nurse what, besides medication, can be done to manage the disease. The nurse will:

A) Breath sounds: Prior to administering Atrovent (Ipratropium Bromide), it is essential for the nurse to assess the child’s breath sounds. Ipratropium is an anticholinergic medication used to relieve bronchospasm in conditions like asthma or chronic obstructive pulmonary disease (COPD). By evaluating breath sounds, the nurse can assess the severity of the respiratory condition and monitor for any wheezing or crackles, which may indicate the need for further intervention or adjustment of the treatment.
B) Cardiac disorders: While some caution may be warranted in patients with cardiac disorders when using certain medications (e.g., sympathomimetics), Ipratropium Bromide is an anticholinergic agent that primarily affects the respiratory system. It is not directly contraindicated in children with cardiac disorders, so assessing for cardiac conditions is not the most critical initial assessment when administering this drug.
C) Recent injuries: Recent injuries do not specifically relate to the need for assessment prior to administering Ipratropium. This medication targets the lungs and airways, so assessing for recent injuries would not be as pertinent unless the injuries impacted the child’s ability to breathe (e.g., rib fractures, lung trauma).
D) Hypertension: Hypertension is not a primary concern when administering Ipratropium Bromide. While anticholinergic drugs should be used cautiously in certain individuals (e.g., those with glaucoma or urinary retention), hypertension is not a contraindication for this medication. It would be more critical to assess for respiratory status, particularly breath sounds, to evaluate the efficacy of the treatment.

A) Interferon-B (IFN-B): Interferon-beta is a disease-modifying therapy (DMT) used for multiple sclerosis (MS) to reduce the frequency and severity of attacks and slow disease progression. However, it is not typically used during an acute exacerbation of MS. It is more commonly prescribed for long-term management of the disease.
B) Mitoxantrone: Mitoxantrone is an immunosuppressive agent that is used as a disease-modifying therapy for patients with more aggressive forms of MS. While it can be helpful in reducing the frequency of attacks, it is not the first-line treatment during an acute relapse. Mitoxantrone is often considered for long-term use when other therapies are not effective.
C) Glatiramer acetate (Copaxone): Glatiramer acetate is another disease-modifying therapy for MS. It works by altering the immune response to protect the myelin sheath. Like interferon-beta, it is used for long-term management, not for acute attacks. It is not typically used during an exacerbation of MS.
D) Methylprednisolone (Solu-Medrol): Methylprednisolone, a corticosteroid, is the standard treatment for acute exacerbations of multiple sclerosis. It works by reducing inflammation, which helps to decrease the severity of symptoms during an MS relapse. The nurse would anticipate this drug being prescribed to manage the acute inflammatory episode and speed recovery from the attack. This medication is often administered intravenously in high doses and then tapered as the patient stabilizes.